IDEXX LABORATORIES INC (IDXX) Stock News
NASDAQ:IDXX - Nasdaq - US45168D1046 - Common Stock - Currency: USD
IDXX Latest News, Press Relases and Analysis
Is IDEXX LABORATORIES INC (NASDAQ:IDXX) suited for quality investing?
A fundamental analysis of (NASDAQ:IDXX): Why NASDAQ:IDXX Stands Out as a Quality Stock.
Should You Invest in the First Trust Water ETF (FIW)?
Sector ETF report for FIW
Is Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) a Strong ETF Right Now?
Smart Beta ETF report for FLQM
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Mentions: ANGO
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day
Here’s Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX)
Baron Funds, an investment management firm, released its “Focused Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Q1 was a difficult start to the year. The fund declined 7.95% (Institutional Shares) in the quarter, compared to the Russell 2500 Growth Index’s (the Benchmark) 10.80% return. Please spare […]
Is The Travelers Companies, Inc. (TRV) the Best Dow Stock?
We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where The Travelers Companies, Inc. (NYSE:TRV) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength […]
Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks
Cardinal Health Inc. (NYSE:CAH) on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17. Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion. Adjusted operating earnings increased 21% to $807 million. Third-quarter sales for the Pharmaceutical and Specialty Solutions segment remained unchanged at $50.6 billion. Third-quarter revenue increased by 20%, excluding the impact of the customer contract expiration, dr
IDEXX Reports Upbeat Q1 Profit, Upgrades Full-Year Guidance: Retail’s Positive
The company has adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market
IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDEXX Laboratories Announces First Quarter Results
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
MedTech bigwigs, such as CVS, HOLX and IDXX, are set to post their quarterly results tomorrow. Can they deliver on expectations?
Waters (WAT) Reports Next Week: Wall Street Expects Earnings Growth
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: WAT
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Jim Cramer on CVS Health Corporation (CVS): “Put up some really good numbers” – New Leadership and Cleaned-Up Stores
We recently published a list of Jim Cramer’s Game Plan for This Week: 16 Stocks in Focus. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer discussed. On Friday, Mad Money host Jim Cramer took a close look at what he […]
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elanco price target lowered to $13 from $16 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on Elanco (ELAN) to $13 from $16 and keeps a Buy rating on the shares. Heading into Q1 earnings, the firm says sentiment on its animal health coverage “skews generally negative,” with a number of broader market and company-specific headwinds. The firm sees limited near-term catalysts to drive estimates higher beyond improved foreign exchange rates, so it thinks shares will remain capped near current levels, the analyst added in a previe
Idexx Laboratories price target lowered to $475 from $535 at BofA
BofA lowered the firm’s price target on Idexx Laboratories (IDXX) to $475 from $535 and keeps a Neutral rating on the shares. Heading into Q1 earnings, the firm says sentiment on its animal health coverage “skews generally negative,” with a number of broader market and company-specific headwinds. The firm sees limited near-term catalysts to drive estimates higher beyond improved foreign exchange rates, so it thinks shares will remain capped near current levels, the analyst added in a preview for
Mentions: MS
Essex Property Trust, Inc. (ESS): Among the Most Profitable Dividend Stocks to Buy Now?
We recently published a list of the 8 Most Profitable Dividend Stocks to Buy Now. In this article, we are going to take a look at where Essex Property Trust, Inc. (NYSE:ESS) stands against other profitable dividend stocks. When it comes to profits, dividend investing is the first thing that springs to mind. Dividends represent a […]
Should You Sell IDEXX Laboratories (IDXX)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, the strategy returned -1.35% (gross) and -1.56% (net) compared to 8.14% for the Russell Midcap Growth Index. In the fourth quarter, the U.S. small […]
IDEXX Laboratories to Release 2025 First Quarter Financial Results
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia. While “disappointed,” the firm says the issues raised were exclusively related to chemistry, manufacturing, and controls, with no concerns cited around the clinical efficacy or safety of etripamil. This reaffirms the integr
Jim Cramer on Netflix, Inc. (NASDAQ:NFLX): “You should own the stock”
We recently published a list of Jim Cramer Says Trump’s Tariff Strategy Is Working & Discusses These 11 Stocks. In this article, we are going to take a look at where Netflix, Inc. (NASDAQ:NFLX) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed […]
Jim Cramer on The AZEK Company Inc. (NYSE:AZEK): “Azek is a very competitive company”
We recently published a list of Jim Cramer Discusses These 11 Stocks & Reveals Why Tech Stocks Are Down. In this article, we are going to take a look at where The AZEK Company Inc. (NYSE:AZEK) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim […]